(trans)-8-({[6-(2-fluorophenyl)-3-pyridazinyl]amino}methyl)-3-(6-methyl-3-pyridinyl)-1-oxa-3-azaspiro[4.5]decan-2-one hydrochloride | 1177267-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (trans)-8-({[6-(2-fluorophenyl)-3-pyridazinyl]amino}methyl)-3-(6-methyl-3-pyridinyl)-1-oxa-3-azaspiro[4.5]decan-2-one hydrochloride
• CAS: 1177267-84-3
• 化学式: C₂₅H₂₆FN₅O₂*ClH
• 分子量: 483.973
• InChiKey: RBOFDMABIQBAID-OUSXTGLOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.41
• 重原子数：
  34.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  80.24
• 氢给体数：
  1.0
• 氢受体数：
  6.0

文献信息

• Spiro Compounds As NPY Y5 Receptor Antagonists
  申请人：Biagetti Matteo

  公开号：US20090203705A1

  公开（公告）日：2009-08-13

  The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C1-C4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; Z 1 is H, C 1 -C 4 alkyl or F; Z is CH 2 , CH(C 1 -C 4 alkyl), C(C 1 -C 4 alkyl) 2 or a bond; A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; or —C(═O)—X; or —O(CH 2 ) 0-1 R 1 ; B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom; R 1 is —(C 1 -C 4 )alkyl(C 1 -C 4 )alkoxy; or C 3 -C 8 cycloalkyl; or R 1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; or R 1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; X is OR 2 or NR 3 R 4 ; R 2 is C 1 -C 4 alkyl; R 3 is hydrogen or together with R 4 and the nitrogen form a 5-6 saturated membered ring; R 4 is C 3 -C 8 cycloalkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.

  本发明涉及式(I)的新化合物或其药学上可接受的盐，其中R是芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；Z1是H、C1-C4烷基或F；Z是CH2、CH(C1-C4烷基)、C(C1-C4烷基)2或键；A是一个6-10成员芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基或—C(═O)—X取代；或—O( )0-1R1；B是氢或是一个5-6成员杂芳基、或一个4-6成员杂环、或苯基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、羟基、氰基取代；A和B通过任何原子连接；R1是—(C1-C4)烷基(C1-C4)氧基；或C3-C8环烷基；或R1是一个芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；或R1是一个4-6成员杂环，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；X是OR2或NR3R4；R2是C1-C4烷基；R3是氢或与R4和氮一起形成一个5-6饱和成员环；R4是C3-C8环烷基；它们的制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们作为NPY Y5受体拮抗剂和用于治疗和/或预防暴饮暴食等进食障碍的药物的用途。